Komori
Human Metabolome Technologies (6090) · FactRestated

Change of Audit Firm

First written in FY2021-Q1. 4 of 5 entries say "Restated". Latest entry: FY2024-Q2.

5entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q1 – FY2024-Q22020: 120202021: 120212022: 120222023: 120232024: 1
Same theme, other companies
Change in the Independent AuditorA theme 769 companies write about · 1 as a headwind · 34 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 769 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q2RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company’s quarterly consolidated financial statements for the second-quarter consolidated accounting period from 1 October 2023 to 31 December 2023 and the second-quarter cumulative period from 1 July 2023 to 31 December 2023 are subject to a quarterly review by 新創監査法人.」

    The Company continues to receive quarterly reviews from 新創監査法人.
  2. FY2023-Q3RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company’s quarterly consolidated financial statements for the third-quarter consolidated accounting period from 1 January 2023 to 31 March 2023 and the third-quarter cumulative period from 1 July 2022 to 31 March 2023 are subject to a quarterly review by 新創監査法人.」

    The Company continues to receive quarterly reviews from 新創監査法人.
  3. FY2023-Q1RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company’s quarterly consolidated financial statements for the first-quarter consolidated accounting period from 1 July 2022 to 30 September 2022 and the first-quarter cumulative period from 1 July 2022 to 30 September 2022 are subject to a quarterly review by 新創監査法人.」

    The Company continues to receive quarterly reviews from 新創監査法人, which changed from the audit firm used in the previous fiscal year.
  4. FY2021-Q2RestatedAnnual report

    「The Company’s quarterly consolidated financial statements are subject to a quarterly review by 新創監査法人.」

    The Company continues to receive quarterly reviews from 新創監査法人, which changed beginning with the first quarter of the 18th fiscal year.
  5. FY2021-Q1First statedAnnual report

    「The Company’s audit firm has changed as follows: 17th consolidated fiscal year: 有限責任監査法人トーマツ; first quarter consolidated accounting period and first-quarter cumulative period of the 18th fiscal year: 新創監査法人.」

    The audit firm changed from 有限責任監査法人トーマツ to 新創監査法人 beginning with the first quarter of the 18th fiscal year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Change of Audit Firm | Human Metabolome Technologies,Inc. (6090) | Komori